Casirivimab and Imdevimab (Ronapreve) – data mapping and interpretation in Exend and Define
Posted in News
Pending the imminent release of Ronapreve, Rx-info has been asked about the best way to describe the items in pharmacy computer systems to prevent ambiguity. We expect this to be a medicine of considerable interest.
Our drug record naming recommendation is that:
- The multidose product is named: Casirivimab 1332mg/11.1 mL with Imdevimab 1332mg/11.1 mL and the dose description is: 2 vial pack
- The Pandemic pack product is named: Casirivimab 300mg/2.5 mL with Imdevimab 300mg/2.5 mL and the dose description is: 2 vial pack
- EMIS users who have access to the DSS Master could also use the RONAPREVE descriptions available.
The aim is to stop the single vials being described separately and provide a consistent concept of what constitutes a pack.
The 2 x 11.1mL multidose product already has a dm+d record and the 2 x 2.5mL pandemic pack concept is anticipated to be published to dm+d on 17/9/21 . Rx-info will then be able to map these from Tuesday 21/9/21 and data will be visible in Define and Exend from Wednesday 22/9/21.
Due to the dm+d concept being a combination pack containing 2 vials, each Ronapreve combination pack will be mapped by Rx-info as 2 vials. Care will thus be needed in interpreting data in Define, Refine and Exend as the separate vials of the combination will be reported.
Please interpret every 2 vials as 1 Ronapreve combination pack.
*Original article published 13/9/21 09:41 updated with drug definition change 16/9/21 18:00